| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
DPP-4
|
|---|---|
| ln Vitro |
SGP8 (0,100 and 500 µM; 24 h) has regulatory effects on lipid metabolism, inflammation and fibrosis[1]. SGP8 (0,100 and 500 µM; 24 h) significantly increased serum GLP-1 levels in vivo and SGP8 has inhibitory activity against DPP4[1]. Real Time qPCR[1] Cell Line: L02 cells Concentration: 0,100 and 500 µM Incubation Time: 24h Result: Improved the mRNA expression of lipid metabolism genes related to Cd36, Scd1, Cpt1 and Pparα and significantly reduced the mRNA expression of inflammatory genes Tnfα, Il-1β, and Ccl5.
|
| ln Vivo |
SGP8 (15 mg/kg, intraperitoneally injected once a day for 4 weeks) alleviates MCD-induced steatohepatitis in mice[1]. SGP8 (15 mg/kg, intraperitoneally injected once a day for 8 weeks) alleviates HFD-induced liver damage and metabolic disorders in mice[1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: L02 Tested Concentrations: 0,100 and 500 µM Incubation Duration: 24h Experimental Results: Reduced the expression of lipid metabolism genes related to CD36, FAS, and SREBP-1 compared to the 1 mM PO model group. Immunofluorescence[1] Cell Types: LX2 Tested Concentrations: 0 and 500 µM Incubation Duration: 24h Experimental Results: Reduced effectively TGFβ1-induced expression of α-SMA and Collagen I protein expression. |
| Animal Protocol |
Animal/Disease Models:Healthy 7-week-old male C57BL/6J mice (22 and 27 g)[1]
Doses: 15 mg/kg; everydays for four weeks Route of Administration: i.g. Experimental Results: Did not reverse the weight loss of mice caused by the MCD diet. Reduces the ratio of liver weight to body weight, as well as liver TG and TC content. Reduces the activities of ALT and AST in the serum of MCD dietinduced NASH mice. Improved liver fibrosis in MCD diet-induced NASH mice. |
| References |
| Molecular Formula |
C34H58N8O11
|
|---|---|
| Molecular Weight |
754.87
|
| CAS # |
855790-98-6
|
| Appearance |
Typically exists as solid at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3247 mL | 6.6237 mL | 13.2473 mL | |
| 5 mM | 0.2649 mL | 1.3247 mL | 2.6495 mL | |
| 10 mM | 0.1325 mL | 0.6624 mL | 1.3247 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
